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a b s t r a c t
Background: Faecal microbiota transplantation (FMT) is a novel potential therapy for inflammatory bowel
diseases, but it is poorly characterised.
Methods: We evaluated the performance of the mouse and rat as a pre-clinical model for human micro-
biota engraftment. We then characterised the effect of a single human stool transfer (HST) on a human-
ised model of DSS-induced colitis. Colonic and faecal microbial communities were analysed using the 16S
rRNA approach and clinical manifestations were assessed in a longitudinal setting.
Findings: The microbial community of rats showed greater similarity to that of humans, while the micro-
biome of mice showed less similarity to that of humans. Moreover, rats captured more human microbial
species than mice after a single HST. Using the rat model, we showed that HST compensated faecal dys-
biosis by restoring alpha-diversity and by increasing the relative abundance of health-related microbial
genera. To some extent, HST also modulated the microbial composition of colonic tissue. These faecal and
colonic microbial communities alterations led to a relative restoration of colon length, and a significant
decrease in both epithelium damage and disease severity. Remarkably, stopping inflammation by remov-
ing DSS before HST caused a faster and greater recovery of both microbiome and clinical manifestation
features.
Interpretation: Our results indicate that the rat outperforms the mouse as a model for human microbiota
engraftment and show that the efficacy of HST can be enhanced when inflammation stimulation is with-
drawn. Finally, our findings support a new therapeutic strategy based on the use FMT combined with
anti-inflammatory drugs.
© 2019 The Author(s). Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Research in context
Evidence before this study
Inflammatory bowel disease (IBD) is a chronic incurable disease
affecting approximately 0.5% of the general population in West-
ern countries. Its aetiology remains unknown and its prevalence
is expected to increase exponentially over the next decade mak-
ing it a growing healthcare burden. Faecal microbiota transplan-
tation (FMT), an efficacious treatment for Clostridium difficile in-
fection, has emerged as a potential therapy for IBD. However, the∗ Corresponding author at: Department of Gastroenterology, Vall d’Hebron Re-
search Institute, Pg Vall d’Hebron, 08035 Barcelona 119-129, Spain.
E-mail address: cmanicha@gmail.com (C. Manichanh).
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2352-3964/© 2019 The Author(s). Published by Elsevier B.V. This is an open access article
(http://creativecommons.org/licenses/by-nc-nd/4.0/)id/long-term effect of this treatment on the evolution of the host
icrobiome, immune response and clinical outcomes has not been
ully investigated through clinical trials nor through proper animal
odels. As a result, the efficiency of current FMT protocols is low
n IBD.
dded value of this study
In the present study, we first show that a conventional rat
odel, more reflective of human microbiota, could be an alterna-
ive to a mouse model to study microbe-host relationships in hu-
an disease. Then, using the humanised rat model of IBD (coli-
is induced by inflammatory agents), we demonstrate that a sin-
le faecal transplantation from a healthy human donor could com-
ensate dysbiosis by restoring alpha-diversity and by increasing
he relative abundance of health-related microbial genera. Further-under the CC BY-NC-ND license.
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ore, we show that the faecal transplantation also corrected, to
ome extent, colonic tissue alterations, leading to a relative restora-
ion of colon length, and a significant decrease in epithelium dam-
ge and disease severity. Finally, we show that stopping the in-
ammation by withdrawing the inflammatory agent before faecal
ransplant results into a faster and greater recovery of both micro-
iome and clinical manifestation features.
mplications of all the available evidence
Our findings lead to promote the use of a rat model, instead
f mouse, as the more appropriate pre-clinical animal model for
MT and IBD. Our first longitudinal study, using a humanised rat
odel of colitis, proves the efficacy of a single faecal microbiota
ransplantation and encourages the use of anti-inflammatory drugs
uring FMT to maintain a remission state in future clinical trials.
. Introduction
Inflammatory bowel disease (IBD) is a complex and chronic in-
estinal disorder associated with an exacerbation of the host im-
une response, a disruption of the intestinal barrier, and alter-
tions in the luminal and mucosal microbial communities [1,2]. IBD
ncludes two chronic intestinal inflammatory forms, ulcerative col-
tis (UC), which affects the rectum and colon, and Crohn’s disease,
hich may involve the entire gastrointestinal tract, but is most
ommon in the colon and terminal ileum [3]. Patients with IBD
xperience episodes of relapse alternating with remission.
Dysbiosis in IBD patients is often characterised by a significant
nd global alteration of the composition and structure of the mi-
robial community and is associated with a lower microbial alpha-
iversity compared to healthy controls [4–7].
Faecal microbiota transplantation (FMT) has been used for sev-
ral years to treat recurrent Clostridium difficile infection (CDI) and
as recently proven effective in randomised clinical trials [8,9]. In-
erest in using FMT to restore a healthy gut microbiota and thereby
ttenuate inflammatory responses in IBD patients is growing. How-
ver, many aspects of this therapeutic approach remain unan-
wered, including questions regarding patient stratification, donor
election and methods to administer the FMT [10–14]. While sev-
ral meta-analyses suggest that FMT is safe, this approach shows
ariable efficacy in IBD patients [12,15,16]. In this regard, more
tudies are required in order to establish optimal and standardised
MT protocols [17]. Concurrently, many experimental models, in-
luding in vivo animal models such as mouse TNBS or DSS-induced
olitis [18,19] and T cell transfer colitis in severe combined immun-
deficient (SCID) mice, have been widely used to study IBD and
he effect of FMT in this disease [20]. For instance, using a mouse
odel of colitis and a short-term follow-up study of 8 days, Zhou
t al. [20] demonstrated that FMT decreases the severity of colitis.
his effect was associated with significantly decreased myeloperox-
dase activity, reduced levels of TNF-α and IL-1β , and an increased
evel of IL-10 in colon tissues. However, these authors did not ad-
ress the impact of FMT on the microbiome community. In this
ontext, to the best of our knowledge, the present study is the first
o evaluate the performance of mouse and rat models for human
icrobiota transplantation.
The aims of this study were to: (a) Identify which animal
pecies (rat or mouse) was the most appropriate to receive and
aintain a single human stool transfer; and (b) to examine the
ong-term effect of a single human stool transfer on a humanised
nd chemically-induced colitis murine model at both microbiome
nd clinical manifestation level.
We demonstrated that the microbiome of rats has a similar
omposition and structure to that of humans, while the micro-
iome of mice shows less similarity to that of humans. More-ver, rats captured more human bacterial species than mice af-
er a single human stool transfer. We then showed that a single
tool transfer, obtained from a previously selected healthy human
onor, modulated the dysbiotic microbiota, which was associated
ith improvements in clinical and biological manifestations.
. Materials and methods
.1. Ethical statement
The animal study was approved by the Ethical Committee
f Animal Experimentation at the Vall d’Hebron Research Insti-
ute (Barcelona, Spain) and the Department of Agriculture, Live-
tock and Fisheries of the Generalitat de Catalunya (Departament
’Agricultura, Ramaderia i Pesca). Animal care complied with the
riteria outlined in the Guide for the Care and Use of Laboratory
nimals Institute for Laboratory Animal Research, Division on Earth
nd Life Studies, Washington, D.C., USA. All experiments were con-
ucted in the animal facilities of the Vall d’Hebron Research Insti-
ute (Barcelona, Spain).
For human stool donors, approval was provided by the Univer-
ity Hospital of Vall d’Hebron Ethics Committee and informed con-
ent was given in all cases.
.2. Animals
Male Sprague-Dawley rats and BALB/c mice were purchased
rom Charles River (France). Rats weighed about 200 g and mice
bout 25 g and were 6 weeks of age. After 7 days of quarantine,
ach animal was isolated in a conventional cage in order to pre-
ent microbial transmission. They were maintained at a constant
oom temperature of 21 °C and were exposed to a 12:12 h light-
ark cycle. All rats drank sterilised water and were fed an auto-
laved standard chow diet. No contact was allowed between rats
ither through water, chow or faeces.
.3. Bowel preparation for stool transfer
Omeprazole was diluted in water, filtered, and administered via
ral gavage at a dosage of 50 mg/kg/day. All animal groups, except
roup A-CTL, received the omeprazole solution on day 2 (9 a.m.),
ay 3 (12 a.m.) and day 4 (8 a.m.). To empty the gastrointestinal
ract, on day 3, rats underwent a 24-h fast and mice a 12-h fast.
nimals were placed individually in a cage to prevent coprophagy
nd they have access to water. Then, 0.2 ml of Citrafleet®, prepared
ollowing the manufacturer’s instructions, was administered twice
9 a.m. and 9 p.m. of day 3) via oral gavage. Citrafleet® (Casen-
leet, Zaragoza, Spain) was administered two times via oral gav-
ge: 1 ml, 24 h before the stool transfer, and 2 ml for rats (1 ml for
ice), 12 h before the transfer [21]. A laparotomy was performed
o evaluate the efficiency of Citrafleet® and to collect colon tis-
ues for microbiome analysis. The use of cages with grids pre-
ented coprophagy during the cleansing procedure, which lasted
bout 24 h. The rats and mice were then given via oral gavage a
ose of omeprazole (at the concentration of 50 mg/kg/day).
.4. Human stool transfer (HST) in mice and in rats
The healthy stool donor was selected in a previous project
Sarrabayrouse et al., unpublished). Briefly, ten healthy volunteers
≥ 18 years of age) provided self-collected stool samples. Two
tools with one month interval were collected and immediately
rozen at home and brought to the laboratory without break-
ng the cold chain, where they were stored at −80 °C. Stool and
erology screenings were performed for bacterial, parasitic and
iral pathogens (Clostridium difficile, Salmonella, Shigella, Yersinia,
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Aeromonas, Campylobacter, Vibrio, E. coli O157, Rotavirus, Adenovirus,
Atrovirus, Norovirus, and Giardia intestinalis). Potential donors did
not take antibiotics in the eight weeks preceding the screening.
One of the donors was selected on the basis of the stability and
high diversity of the stool microbial community and the lack of
genera potentially involved in inflammation, such as Escherichia or
Fusobacteria, and the presence of Faecalibacterium. The transfer of
human stool to rodents was performed once through an oral gav-
age using 100 mg of a fresh stool sample diluted in 2 ml of PBS for
rats (in 1 ml for mice). A second HST containing 100 mg of faeces
diluted in 2 ml of PBS was performed 22 days after the induction
of colitis. Faecal samples were collected at various time points.
2.5. Induction and assessment of colitis by administration of DSS in
rats
Rats were provided with drinking water containing 5% (wt/vol)
dextran sodium sulphate (DSS) (mol wt 40,000; TdB Consultancy,
Uppsala, Sweden) ad libitum for 5 days in order to induce acute
experimental colitis. Chronic colitis was then induced by reduc-
ing the concentration of DSS to 2% for 17 (group Dw-DSS) or 57
(group D) days depending on the study group, as previously de-
scribed by Oishi et al. [22]. Colitis was assessed daily on the basis
of the combined scores of body weight, stool consistency and pres-
ence of macroscopic blood in stools to calculate disease activity in-
dex (DAI), as shown in Supplementary Table S1. The DAI score was
graded on a scale of 0–4, as previously described by Murthy et al.
[23].
2.6. Laparotomy and euthanasia
On the last day of the study, laparotomy was performed by in-
jecting 10 mg/kg xylazine (Xilagesic®; Calier, Barcelona, Spain) and
75 mg/kg ketamine (Ketolar®; Parke-Dawis, Madrid, Spain). The
whole intestine was removed and the colon was washed with PBS
and cut into small pieces. Some of the colon fragments were sam-
pled for histological evaluation while others were stored directly at
−80 °C for microbiome analyses.
2.7. Histological analysis
For histology, tissues were fixed in Methanol-Carnoy’s solution
(60% methanol, 30% chloroform, 10% glacial acetic acid) and main-
tained at room temperature for at least 3 h. Small pieces of colon
tissue were placed into cassettes and dehydrated in ethanol baths.
They were then immersed in xylene, a clearing agent, to remove
ethanol. Next, colon tissues were embedded in molten paraffin and
sectioned (5 μm). Slices were stained with hematoxylin and eosin.
Finally, the degree of intestinal inflammation was determined fol-
lowing the guide described by Erben et al. [24].
2.8. TNF-α measurement
TNF-α was determined in tissue samples by enzyme-linked im-
munosorbent assays (ELISAs), following the manufacturer’s proto-
cols (eBiosciences). Results are expressed as the ratio of picograms
of TNF-α per milligram of total protein. Limits of detection were
30 pg/ml.
2.9. Lymphocyte isolation and staining from spleen
Single cell suspensions were generated from spleens, and ery-
throcytes were removed from splenic samples by Ficoll gradi-
ent centrifugation. 2.5 × 10^5 splenocytes were stained with FITC-
conjugated anti-CD3 (Miltenyi Biotec), PB-conjugated anti-CD4 and
PE-conjugated anti-CD8 antibodies. Stained cells were analysed byow cytometry using an LSRFortessa cytometer (BD) and then
nalysed with FlowJo software (FlowJo LLC).
.10. Microbiome analysis
.10.1. 16S rRNA gene amplification
Genomic DNA was extracted using the protocols previously de-
cribed by Pascal et al. [7] for stool samples and by Santiago et al.
25] for tissue samples. An equivalent of 1 mg of each sample
as used for DNA quantification using a Nanodrop ND-1000 Spec-
rophotometer (Nucliber). DNA integrity was examined by micro-
apillary electrophoresis using an Agilent 2100 Bioanalyzer with
he DNA 12,000 kit.
For profiling microbiome composition, the hyper-variable region
V4) of the bacterial and archaeal 16S rRNA gene was amplified
y PCR using universal primers, as previously described by Pascal
t al. Standard PCR using 0.75 units of Taq polymerase (Roche) and
0 pmol/μL of the forward and reverse primers was run in a Mas-
ercycler gradient (Eppendorf) at 94 °C for 3 min, followed by 35
ycles of 94 °C for 45 sec, 56 °C for 60 sec, 72 °C for 90 s, and a final
ycle of 72 °C for 10 min. Amplicons were first purified using the
IAquick PCR Purification Kit (Qiagen, Barcelona, Spain), quantified
sing a Nanodrop ND-1000 Spectrophotometer (Nucliber) and then
ooled in equal concentration. For colon samples, a second purifi-
ation step was applied to the pool of amplicons, as described in
antiago et al. [25]. The pooled amplicons (2 nM) were then sub-
ected to sequencing using Illumina MiSeq technology at the tech-
ical support unit of the Autonomous University of Barcelona (UAB,
pain), following standard Illumina platform protocols. In order to
dentify possible contamination in colonic tissues, considered as
ow-biomass samples, and subtract the sequences of the potentially
ontaminated DNA generated, negative controls (blanks) were in-
roduced during two technical steps: genomic DNA extraction and
6S rRNA gene PCR amplifications.
.10.2. Upstream 16S rRNA sequence analysis
The upstream sequence analysis was performed with QIIME
v.1.9.0) using the guidelines proposed by Navas-Molina [26]. First,
e generated a mapping file containing sample identifiers, bar-
odes, primer sequences, time points, symptoms, treatments and
ny other additional information of the samples needed for the
nalyses and validated its compatibility with the QIIME tool. Then,
e demultiplexed and performed sequence quality filtering of the
btained fastq files with a minimum acceptable Phred score of 20.
rom a total of 531 rat faecal samples, we obtained a total of 23.8
illions of high-quality sequences with a number of reads rang-
ng from 1 to 85,679 per sample with an average of 44,201 reads.
rom a total of 36 rat colon samples, we obtained a total of 4.6
illions of high-quality sequences with a number of reads ranging
rom 3711 to 460,161 per sample with an average of 127,934 reads.
rom a total of 60 mice faecal samples, we obtained a total of 2.8
illions of high-quality sequences with a number of reads ranging
rom 22,663 to 69,572 per sample with an average of 46,230 reads.
We clustered similar filtered sequences into Operational Tax-
nomic Units (OTUs) with the USEARCH algorithm (v8.1.1861)
27] using a 97% similarity threshold. Although the QIIME devel-
pers recommend the open-reference method that first groups se-
uences using a reference database and then by sequence iden-
ity, we preferred, in terms of time consumption and discovery of
ovel diversity, to use the de novo approach, based only on se-
uence similarity that focuses on finding new bacteria. In this step,
e also identified and removed chimeric sequences using UCHIME
27].
We then performed a taxonomical assignment step using the
asic Local Alignment Search Tool (BLAST) to map each representa-
ive sequence against a combined database of Greengenes (gg_13_8
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elease) and PATRIC databases. Since each OTU could comprise
any related sequences, we picked a representative sequence from
ach OTU and these representative sequences were aligned using
yNAST against Greengenes template alignment. After this step, we
id a phylogenetic construction with FastTree. Finally, we gener-
ted a table containing the predicted taxonomy and abundance of
ll the OTUs for each sample.
.10.3. Removal of unknown sequences not corresponding to the 16S
RNA gene
In the case of colon (low biomass) samples, many of the se-
uences could correspond to unknown taxa, which could be due to
he presence of Eukaryotic host sequences. We identified those se-
uences assigned as unknown by mapping them against GenBank
sing BLAST and we removed from the OTU table all sequences
hat did not correspond to the 16S rRNA gene.
.10.4. Removal of bacterial contaminants
After removal of non-bacterial DNA, we identified bacterial con-
amination in colon samples and removed it. We used the ’preva-
ence’ method of the open-source R package decontam [28] with
oth extraction and PCR negative controls and with the default
hreshold (P = 0.1). We decontaminated each sequencing run sep-
rately.
.10.5. Downstream sequence analysis
We performed downstream analyses, including diversity analy-
es and statistical tests with QIIME (v1.9.1) and R software (v3.4.4).
e used the biom program to convert tables between biom and
xt formats. We assigned arbitrary numbers to unknown species to
void collapsing possible novel species into one. Finally, we sum-
arised the OTU table by distinct taxonomic levels from phylum
L2) to species (L7).
.10.6. Diversity
We performed rarefaction (random selection of the same num-
er of reads per sample) in the OTU table in order to account for
neven library sizes. For rat faecal samples, we rarefied the OTU
able at 10,912 sequences per sample, which allowed us to keep
21 samples and 16.42 million reads for further analyses. For the
nalyses involving human and rat faecal samples, we rarefied the
TU table at 7512 sequences per sample (in order to keep most of
he samples) and retained 524 samples and 16.46 million reads for
urther analyses. For rat colon samples, we rarefied the OTU table
t 2538 sequences per sample, which maintained all 36 samples
nd 2.81 million reads for further analyses. Regarding mice faecal
amples, we rarefied the OTU table at 7512 sequences per sam-
le, which retained all 60 samples and 2.8 million reads for further
nalyses.
To estimate the alpha-diversity (within samples), we calculated
he Chao1 and Shannon indexes [29,30]. Beta diversity (between
amples) was computed using weighted and unweighted UniFrac
31] to produce distance matrices, which were later used for
rouping samples into hierarchical cluster trees with unweighted
air Group Method with Arithmetic mean (UPGMA) and Principal
oordinate Analyses representations (PCoA).
.10.7. Differential abundance and statistics
To assess differences in the microbiota composition between
roups based on treatment and/or time point, we used the non-
arametric statistical Kruskal-Wallis test (more than two groups,
npaired), Wilcoxon signed rank test (pairwise paired compar-
sons) and Mann-Whitney U test (pairwise unpaired comparisons).
o account for multiple comparisons of all taxa, we used FDR cor-
ection and considered the results significant when P < 0.1. Then,o compute correlations between the microbiota and clinical or ex-
erimental variables, we used non-parametric Spearman correla-
ions. For the statistical analysis of clinical longitudinal data, we
sed a non-parametric method of the R package nparLD (https:
/CRAN.R-project.org/package=nparLD).
.10.8. Microbial source tracking
Microbial source tracking was performed using SourceTracker
v1.0.1) [32], a Bayesian approach that estimates the proportion
f OTUs in a given community that come from possible source
nvironments. We used the default parameters (burn-in = 100,
estart = 10, alpha and beta Dirichlet parameters = 0.001 and 0.01,
espectively), except for the rarefaction depth, which was set to
512, as in the analyses involving human and rat faecal samples.
o analyse the effect of HST in the two rodent models, mouse and
at faecal samples from the first day of the trial and HST donor
amples were defined as mouse, rat and human sources, respec-
ively. To determine the proportions of healthy rat microbiota ver-
us microbiota associated with the administration of DSS, rat fae-
al samples from the day after DSS administration and from af-
er 3 weeks of DSS treatment were defined as healthy and DSS-
ssociated sources and used to train the model. The rest of samples
ere then assigned some percentages either from these sources or
n unknown source.
.10.9. Data deposition and accession numbers for raw data
Sequence data and metadata have been deposited in the Gen-
ank database with the following access number: PRJNA549436.
. Results
.1. Choice of rodent model
.1.1. Rat microbiome compared to mouse and human microbiome
Conventional mice are often used to study human diseases and,
n particular, to examine the effect of alterations in the micro-
ial community in human diseases. To study whether conventional
ats outperform mice as recipients for human microbiota, we first
ompared the faecal microbiome of rats (n = 52), mice (n = 16) and
ealthy human individuals (n = 72). Human sequence data were re-
overed from our previous study [7] and data for rats and mice
ere newly generated.
Firmicutes and Bacteroidetes accounted for 93%, 98% and 93% of
he sequence data in the human, mouse and rat microbiome, re-
pectively (Fig. 1(a)). The microbial faecal community of the three
pecies was significantly different for the most predominant phyla
nd genera (Mann Whitney pairwise test, FDR < 0.05). Alpha-
iversity analysis using Chao1 estimates showed significant pair-
ise differences between the three groups (Fig. 1(b)). Shannon in-
exes revealed significant pairwise differences between all groups,
xcept between mice and humans (Fig. 1(c)). Altogether, mice pre-
ented a higher alpha-diversity than rats and humans. Surprisingly,
eta-diversity analysis, based on weighted and unweighted UniFrac
ndexes, revealed that the distance between rats and humans was
maller than that between mice and humans (Fig. 1(d)–(g)). These
ndings confirmed that the faecal microbial community of rats is
ore similar to that of humans than that of mice to humans.
.1.2. Human stool transfer (HST) in rats and mice
Human microbiota-associated (HMA) animal models are becom-
ng a standard tool through which to study the relation between
ut microorganisms and human diseases. We performed a HST into
onventional rat and mouse by gavage to evaluate how each ro-
ent shaped the human microbiota over time (Fig. 1(h)). Omepra-
ole, a proton pump inhibitor, was used to suppress stomach acid
ecretion and therefore to increase bacterial survival. CitraFleet®
634 M. Lleal, G. Sarrabayrouse and J. Willamil et al. / EBioMedicine 48 (2019) 630–641
Fig. 1. The microbiome of the rat showed greater similarity to that of humans than the mouse microbiome to humans. (a) Taxonomic profile at the phylum level for
human (n = 72), rat (n = 52) and mouse (n = 16) faecal samples. Alpha-diversity analysis using the Chao1 (b) and the Shannon (c) indexes showed differences between
humans, mice and rats (FDR < 0.05). Pairwise distances between rats and humans were lower than between mice and humans in both unweighted (d) and weighted (e)
UniFrac (FDR < 0.05). Unweighted (f) and weighted (g) UniFrac Principal Coordinate Analysis representation of the three species, highlighting the HST donor sample. (h)
Experimental design to assess the engraftment of the human microbiota in mouse and rat. (i) Proportion of predicted microbiota from a human source in rats and mice
allocated to different groups as a function of receiving a HST. Significant differences were found between rats receiving a HST or not, and also between rats and mice
receiving a HST (Mann-Whitney U test; p < 0.05). NM = No HST mouse; HM = HST mouse; NR = No HST rat; HR = HST rat.
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(sodium picosulfate), a stimulant laxative, was used to empty the
gastrointestinal tract before the HST. The healthy human donor
stool was previously selected from ten volunteers on the basis of
its high microbial diversity and stability, and tested for the absence
of potential common pathogens (see Methods section). Addition-
ally, the healthy donor stool was selected for having the lowest
relative abundance of Escherichia and Fusobacteria and a high abun-
dance of Faecalibacterium, characteristics of a healthy stool as com-
pared with an IBD stool [7] (see Methods section). To monitor the
evolution of the transferred human microbiome in the rodents, we
used SourceTracker, a Bayesian, OTU-based algorithm, to estimate
the proportion of the human microbial community remaining in
the animals over time, up to 8 weeks (60 days) for mice and 16
weeks (112 days) for rats. To train the model, we used rat and
mouse faecal samples collected immediately after quarantine, and
the healthy human donor sample. Surprisingly, the proportion of
the human microbiome present in the rats was significantly higher
than in mice over the 8-week follow-up (Fig. 1(i), day 60), thereby
suggesting that rats captured human microbiota more efficiently
than mice. The engraftment effect lasted for at least 38 days and
was lost at 60 days. sGiven that the rat microbiome was more similar to the hu-
an microbiome, in terms of composition and structure, than
he mouse microbiome to humans and that it showed a better
nd long-lasting engraftment of this human microbiome, the rat
merges as a better model for studying the relationship between
he microbiome and human intestinal diseases.
.2. Modulation of the rat gut microbiota
.2.1. Experimental design
To assess the effect of a HST in a rat model of chronic intesti-
al inflammation, a total of 50 animals were randomly placed into
even experimental groups (Fig. 2) as follows: a control group re-
eiving a standard diet and water without treatment (group A-
TL, same group as that described in Fig. 1(h) as NR); a group
eceiving omeprazole and Citrafleet® (group B-OME-CIT), to evalu-
te the cleansing effect; a group receiving omeprazole, Citrafleet®
nd a human stool (group C–HST1, same group as that described
n Fig. 1(h) as HR), to evaluate the humanization protocol; a group
eceiving omeprazole, Citrafleet®, human stool and then dextran
odium sulfate (DSS) until the end of the study (group D), to
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Fig. 2. Experimental design to evaluate the effect of a human stool transfer on a
rat model of chronic intestinal inflammation. Seven groups were distributed as fol-
lows: a control group receiving a standard diet and water without treatment (group
A-CTL, n = 10); a group receiving omeprazole and Citrafleet® (group B-OME-CIT,
n = 8); a group receiving omeprazole, Citrafleet® and a human stool (group C–HST1,
n = 8); a group receiving omeprazole, Citrafleet®, human stool, and DSS until day
39, which was replaced by water (w) until the end of the study (group Dw-DSS,
n = 7); a group receiving omeprazole, Citrafleet®, human stool and then DSS un-
til the end of the study (group d-DSS, n = 7); a group receiving omeprazole, Cit-
rafleet®, human stool, and DSS until day 39, which was replaced by water (w) until
the end of the study, and a second human stool (group Ew-HST2, n = 7); a group
receiving omeprazole, Citrafleet®, human stool, DSS until the end of the study, and
a second human stool (group E-HST2, n = 7). HST: Human stool transfer; DSS: dex-
tran sodium sulfate. The “n” in the right side of the figure represents the number
of animals for which colonic tissues were collected and analysed for microbiome
composition.
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valuate dysbiosis after inflammation induction; a group receiv-
ng omeprazole, Citrafleet®, human stool, DSS until the end of the
tudy and a second human stool (HST2) on day 39 (group E-HST2),
o assess the effect of microbiome modulation in response to the
ransfer of a healthy human stool.
Two additional groups, Dw-DSS and Ew-HST2, were added.
hese were similar to groups d-DSS and E-HST2, except that DSS
as replaced by water at day 39 before HST2, in order to study
he resilience of the mucosal layer and the microbiota after injury
o the tissue was stopped. As specified above, omeprazole and Cit-
aFleet® were used to increase microbial survival and to empty the
astrointestinal tract, respectively, before stool transfer. DSS was
sed to induce chronic intestinal inflammation, which occurred af-
er 5 days of DSS treatment at 5% and then at 2% (group d-DSS vs.
w-DSS and group E-HST2 vs. Ew-HST2).
The first HST was performed to generate a human microbiota-
ssociated animal model and the second to assess the correction
f disease severity (group E-HST2 vs. d-DSS and group Ew-HST2vs.
w-DSS). Given that human microbiota differs significantly from
hat of rodents, the transfer of human microbiota was performed
o ensure a human microbiota context before inducing inflamma-
ion.
In order to calculate the disease activity index (DAI), animals
ere monitored daily for body weight and for the presence of
lood in stool. Histological, immunological and colonic microbial
ommunity analyses were performed on colonic samples obtained
n the day of sacrifice. Faecal microbial community and DAI scores
ere evaluated at various time points.
.2.2. Rat intestinal microbial community viewed across time
To study the effect of time on the faecal microbial composi-
ion, we analysed changes in the taxonomic profile over 16 weeks
112 days, animal group A-CTL) of follow-up (Fig. 3(a)). The rel-
tive abundance of six phyla (Fig. 3(b)) and ten genera changed
ignificantly over 16 weeks, with an increase in Adlercreutzia, Sut-erella, Prevotella, Bacteroides, Odoribacter, and three unknown gen-
ra from Rikenellaceae, Desulfvibrionaceae and S24-7 families, and
decrease or disappearance of Lachnospira and Parabacteroides
Fig. 3(c)). Changes in the taxonomic profile were associated with a
ignificant increase in alpha-diversity, as shown by the Chao1 and
hannon indexes and the number of observed species from D0 to
112, which increased from 161 to 289 (Fig. 3(d)–(f)).
.2.3. Short-term effect of bowel cleansing
The short-term effect of omeprazole alone on the gut microbial
ommunity was not significant (animal group B-OME-CIT). How-
ver, omeprazole combined with CitraFleet® led to an increase
n Verrucomicrobia and Proteobacteria but a decrease in Firmi-
utes (Supplementary Fig. S1a). At the genus level, omeprazole and
itraFleet® led to increases in several genera, such as Parabac-
eroides, Morganella and Citrobacter and deceases in others, includ-
ng Anaerostipes, unknown Clostridiales, and Lactobacillus, among
thers (Supplementary Fig. S1b). To the best of our knowledge, this
s the first study to report this combined effect of omeprazole and
itraFleet® on the composition of the gut microbial community.
.2.4. Inflammation and dysbiosis induction
To simulate human IBD, we induced inflammation using dex-
ran sodium sulfate (DSS) in two additional animal groups, d-DSS
nd Dw-DSS. DSS, a negatively charged sulphated polysaccharide,
as given in drinking water at 5% (from day 17) and then at 2%
from day 22) in order to achieve a model of chronic intestinal in-
ammation [22]. The Dw-DSS group was used to assess resilience
fter withdrawal of DSS treatment on day 39 (Fig. 3). DSS re-
ults in the death of epithelial cells, leading to the disruption of
he epithelial monolayer lining. This disruption allows the entry
f luminal bacteria and associated antigens into the mucosa and
auses an altered mucosal immune response [19]. Small intestine
nd colon lengths, like the histological scores, were measured on
he day each animal was sacrificed. A blinded histological evalua-
ion of colonic tissues was performed by two researchers on the
ay of animal sacrifice.
Significant alterations in the faecal microbial communities were
bserved at the genus level when comparing the two groups of
ats with (D-DSS) and without (C–HST1) DSS treatment at day 79.
s shown in Fig. 4(a), changes in the microbial community induced
y DSS included genera that were significantly affected over time
Fig. 3(b)), such as Bacteroides, Suterella and an unknown mem-
er of the S24-7 family. Bacteroides and Suterella increased both
ver time and upon DSS treatment. Conversely, the unknown S24-7
roup increased over time but decreased in response to DSS. These
ndings suggest that the S24-7 group is involved in maintaining
omeostasis in the gut microbiota. No significant correlations were
ound in colonic tissues—an observation that could be attributed
o the low number of samples involved. Notably, the microbiome
eturned to a baseline and healthier composition when DSS treat-
ent was withdrawn, as shown by SourceTracker (Fig. 4(b)). In-
eed, no significant differences were found at the genus level be-
ween groups C–HST1 and Dw-DSS.
To determine whether the dysbiosis in a rat model of DSS-
nduced colitis was similar to ulcerative colitis or to Crohn’s dis-
ase in humans, we compared the microbiome data of rats from
roup d-DSS collected at day 116 with published sequence data
7] of adult patients with ulcerative colitis (UC, n = 28) and adult
atients with Crohn’s disease (CD, n = 32), using the UniFrac dis-
ances. Our results showed that dysbiosis in the rat model of
SS-induced colitis was closer to dysbiosis in patients with UC
han in those with CD, when taking into account only microbial
omposition (unweighted UniFrac distances) (non-parametric test,
< 0.01) (Fig. 4(c) and (d)). This result validates the description of
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Fig. 3. Evolution of the rat microbiome over time (112 days). (a) Taxonomic profile at the phylum level. Significant differences (marked with asterisks) were found in most of
the phyla over time (Kruskal-Wallis test, FDR < 0.05). Each bar represents an individual faecal sample. (b) Taxonomic profile at the genus level, only significant changes are
shown (Kruskal-Wallis test, FDR < 0.05). Each bar represents an individual faecal sample. Alpha-diversity was calculated on the basis of the species observed (c), the Chao1
index (d), and the Shannon index (e). Significant differences were found in all three indexes, indicating a progressive increase in microbial diversity over time (FDR < 0.05;
∗∗: FDR < 0.01; I: FDR < 0.1). A total of 24 faecal samples were analysed, with n = 4 or n = 6 at each time point.
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several clinical characteristics of the rat model, such as colon lo-
calization and the lack of transmural inflammation, as reported in
this study and others [33].
As shown in Fig. 5(a), small intestine length was not affected
by DSS treatment. In contrast, colon length was significantly re-
duced in all animal groups compared to the control group C–HST1,
as reported by others (Fig. 5(b)) [19,23,34]. The mucosal layer of
group d-DSS was highly damaged compared to group C–HST1, as
shown by an average histological score of 4.4 (SD = 1.1) vs. 1.7
(SD = 0.8), respectively (Fig. 5(c) and (d)). When DSS treatment
was withdrawn from group Dw-DSS, which implied that mucosal
tissues were not exposed to DSS for 40 days, we observed a sig-
nificant recovery from tissue damage, as shown by an average his-
tological score of 2.9 (SD = 0.8). Furthermore, disease activity in-
dexes (DAI), which were calculated on the basis of animal weight,
presence of blood in stool and stool consistency scores for each an-
imal at different time points, significantly increased in group d-DSS
compared to Dw-DSS (mixed ANOVA, P < 0.05) when DSS admin-
istration was stopped on day 39 (Fig. 5(e)).
Moreover, to evaluate the immune response associated with
DSS treatment, we studied the frequency of CD4 splenic T lympho-
cytes in spleen and measured TNF-α in colonic tissues. To this end,
splenocytes were isolated and analysed by flow cytometry, as de-
scribed in the Methods section. On the one hand, we observed that
humanization of the rats decreased the frequency of these cells,
thereby suggesting that the human microbial community affectedhe peripheral immune response of the animals (Fig. 5(f)). On the
ther hand, DSS significantly increased the frequency of these cells,
hich is in agreement with an increase in the inflammation in-
uced by this treatment. When DSS was maintained until the end
f the study, no effect on the production of TNF-α in colonic tis-
ues was observed; however, a significant decrease in this param-
ter was detected when DSS was stopped on day 39 (Fig. 5(g)).
All together, these results demonstrate that, as expected, DSS
nduced a significant reduction in colon length and mucosal dam-
ge. Moreover, it exacerbated the immune response and caused an
ncrease in disease severity. Furthermore, cessation of DSS after a
aily treatment of 22 days revealed an improvement of all these
linical and biological manifestations.
.2.5. Correction of dysbiosis and disease severity by HST
To evaluate the therapeutic potential of HST to correct DSS-
nduced inflammation, we added two animal groups, E-HST2 and
w-HST2, in which we performed a second HST (HST2) on day
9 (22 days after the start of DSS-induced inflammation). The Ew-
ST2 group was added to assess the resilience of rats after with-
rawal of the DSS treatment (see experimental design in Fig. 2).
Analysis of group E-HST2 revealed a significant reversal of ep-
thelial damage as compared with group d-DSS, as shown by a rel-
tive reduction of the histological score (P = 0.07; Mann-Whitney
test) and a significant reduction of the DAI score (P = 0.003;
non-parametric mixed ANOVA-like test). Rats did not present dif-
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Fig. 4. DSS administration causes dysbiosis in rats. (a) Significant differences in the relative abundance of several microbial genera between group C–HST1 and D (no DSS
vs. 9 weeks DSS) at the end of the trial (at day 79). (b) Proportion of predicted microbiota from a healthy rat source in rat groups C, D and Dw-DSS, using the SourceTracker
software. The vertical, dotted line separates the time points of the 3 weeks in which rats in group Dw-DSS received DSS (left) from the rest of time points in which DSS
treatment was withdrawn (right). Significant differences were found between DSS-treated rats and untreated rats (group C–HST1 vs. D) but not between control rats and
rats after DSS treatment was withdrawn (group C–HST1 vs. Dw-DSS, at day 60) (Mann-Whitney U test; p < 0.05). (c) Unweighted UniFrac distances between rats in group
d-DSS (9 weeks DSS) and UC and CD patients. Significant differences were found, UC patients being closer to rats with DSS-induced colitis than CD patients to this rat model
(non-parametric test, p < 0.01). (d) Weighted UniFrac distances between rats with DSS-induced colitis in group d-DSS (9 weeks DSS) and human UC and CD patients. No
significant differences were found.
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erences in small intestine length with (E-HST2) or without (Ew-
ST2) the maintenance of colitis induction. However, colon length
ended to increase in group E-HST2 compared to D (Mann-Whitney
test, P = 0.08) (Fig. 5(a) and (b)). Of note, HST2 significantly de-
reased the frequency of CD4 splenic T lymphocytes (group d-DSS
s. E-HST2), reducing it to basal level (group C–HST1). This find-
ng therefore indicates the efficacy of this treatment on one of the
arkers of inflammation. At the faecal microbiome level, HST per-
ormed in group E-HST2 increased alpha-diversity (Chao1 indexes)
s compared with group d-DSS (FDR = 0.057, on the day of sacri-
ce (Fig. 6(a) and (b)).
HST2 in group Ew-HST2 caused a significant decrease in dis-
ase severity through a reduction in both the DAI scores (P = 1e-
3; non-parametric mixed ANOVA-like test) and histological scores
P = 0.005; Mann-Whitney U test) compared to the group that re-
eived DSS (D) (Fig. 5(c) and (d)). Simultaneously, at the micro-
iome level, we observed a recovery of alpha-diversity (Fig. 6(a)
nd (b)) and a greater proportion of healthier gut microbiota, us-
ng the SourceTracker method, in both faecal samples and colonic
issues (Supplementary Fig. S2).
Furthermore, the Spearman correlation test revealed correla-
ions between colonic microbiome composition and clinical man-
festations such as DAI scores, histological scores and colon length.
ndeed, several microbial phyla and genera in the colonic tissues
howed a correlation with colon length and DAI scores (Fig. 6(d)
nd (e)). Ruminococcus, Lactobacillus and an unknown Ruminococ-
aceae were positively correlated with colon length, and an un-
nown Erysipelotrichaceae and Bacteroides were negatively corre-
ated with this parameter. In contrast, an unknown Rikenellaceae
as positively correlated with DAI scores, and Oscillospira, an un-
nown Christensenellaceae and an unknown genus of Mollicutes
lass were negatively correlated with these scores. oFinally, we also found several correlations between faecal mi-
robiome and clinical manifestation. Among them, an unknown
uminococcaceae and Ruminococcus were positively correlated
ith colon length and negatively with histological score. The S24-
group was positively correlated only with colon length. Con-
ersely, Bacteroides was negatively correlated with colon length but
ositively correlated with histological score. The longitudinal set-
ing allowed us to assess the effect of the different treatments on
he relative abundance of various microbial genera, which evolved
s expected from their correlations with clinical manifestations
Fig. 6(f)).
. Discussion
Here we first studied the performance of the rat and mouse for
ST. We then evaluated the therapeutic potential of a stool trans-
er to treat chronic inflammation induced by a colitogenic chemi-
al. To this end, we analysed clinical manifestations and immuno-
ogical markers, as well as faecal and colonic microbiota in a lon-
itudinal setting (up to about 100 days) using a conventional an-
mal model. Our experimental design, which included several ani-
al groups, also allowed us to gather information on the natural
volution of the animal gut microbiome over a period of 112 days,
he long-term effect of colitis induction, and the resilience of the
icrobiome when this induction was stopped.
Most studies on IBD using DSS-induced colitis models have
een performed on mice [20,33–35]. Comparison of rat, mouse
nd human genomes has revealed that the rat genome contains
bout the same number of genes as that of humans and mice
36]. A recent study has provided a gene catalogue of the Sprague-
awley rat gut metagenome, and comparison of rat with human
r mouse has revealed a higher pairwise overlap between rats and
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Fig. 5. HST ameliorated clinical manifestations during DSS-induced colitis. Small intestine (a) and colon length (b) measured on the day of sacrifice. (c) Histological scores.
(d) Haematoxylin and eosin staining of colonic tissue. (e) Disease activity indexes (DAI) were calculated on the basis of animal weight, presence of blood in stool and stool
consistency scores for each animal. Significant differences were found using a non-parametric test equivalent to a mixed ANOVA (P < 0.05, the different letters (a, b and c)
indicate which groups were different). (f) Lymphocyte isolation from spleen. (g) TNF-α measurement in colonic tissues. Mann Whitney test, ∗: P < 0.05; ∗∗: P < 0.01.
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humans (2.47%) than between mice and humans (1.19%) at the
gene level [37]. Our study, using 16S rRNA sequence data, has com-
plemented this previous work, showing that the overall composi-
tion and structure of the faecal microbiome of rat has a greater
similarity to that of the human than the microbiome of the mouse
to human. Furthermore, the rat appeared to capture the human
stool microbiome more efficiently than the mouse. Overall, on the
basis of these findings, the rat emerges as a potential alternative
to the mouse for evaluating a human microbiota-associated ro-
dent, thus highlighting the potential use of rats to study the effectf FMT in treating IBD and other human disorders. Future studies
hould test the effects of transplanting stools with diverse micro-
ial compositions from various human donors and evaluate a range
f conditions to improve the engraftment of human microbiota.
or instance, using a mouse model, a recent paper by Staley et al.
38] has shown that an appropriate antibiotic treatment protocol
ollowed by a single gavage of human microbiota provides a useful,
omplimentary human microbiota-associated model to that estab-
ished in germ-free facilities. A similar protocol could be applied
o the rat model, although in the case of a colitis model, the use
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Fig. 6. Effect of HST on DSS-induced dysbiosis. (a) Alpha-diversity in stool samples as measured by the Chao1 indexes in a longitudinal setting. Alpha-diversity in stool (b)
and colon (c) samples as measured by the Chao1 indexes on the day of animal sacrifice. There was a significant reduction in faecal microbiome diversity only in group
d-DSS compared to control group C–HST1 (n = 5–8 per group, non-parametric test, FDR < 0.1). No significant differences were found in the colonic microbiome (n = 4–6
per group). Correlations between microbiome composition in colonic tissues and clinical manifestations as measured by the Spearman correlation test (P < 0.05). In colon
samples, genera were significantly correlated with colon length (d) and with DAI score (e). (f) In stool samples, the evolution of several bacterial genera selected based on
their correlation with clinical manifestations are plotted according to the longitudinal setting.
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of an antibiotic cocktail could cause a bloom of Escherichia (Pro-
teobacteria), which may sustain inflammation. This protocol would
therefore need further evaluation on a model of colitis.
Our study presented several limitations. We used a 16S rRNA
gene approach to characterise changes in the microbial community.
Indeed, to evaluate the effect of treatments, more comprehensive
approaches could have been applied. These include DNA and RNA
shotgun sequencing, proteomic or metabolomic analysis. However,
these approaches are also much more expensive and may not be
worth this project using an animal model. Another limitation of
the present work is the use of only one colitis model, which may
not reproduce all the characteristics of human chronic UC. Another
in vivo model such as TNBS-induced colitis might have provided
different outcomes. However, DSS is used in many studies for its
simplicity (given in drinking water and not by enema administra-
tion as for TNBS) and a relative short time to induce chronic coli-
tis. Moreover, the evaluation of the combined effect of Citrafleet®
and omeprazole unexpectedly uncovered a dramatic alteration of
the microbiome composition. However, we did not assess whether
this treatment could influence donor microbiome engraftment or
dysbiosis caused by DSS. Future studies should provide details of
the long-term effect of these drugs on engraftment and include an-
other control group without this treatment. Finally, we performed
HST using a single faecal sample collected from only one healthy
donor. This approach did not therefore allow testing of whether a
specific microbial community composition affects the efficiency of
colonization and recipient immune response. Future studies could
also test the effects of stool transfers at several time points on the
efficiency of this procedure.
Our longitudinal study has provided valuable information re-
garding the natural evolution of the rat faecal microbiome over
112 days, demonstrating a continuous increase in alpha-diversity
and changes in composition. These results suggest that, although
rats reach sexual maturity at six weeks of age, their gut micro-
bial community may still be developing until at least five months
of age, the age that these rats reached after the 112-day follow-
up. We propose that future studies determine the age at which
rats should be tested in order to achieve greater stool transfer effi-
ciency. Moreover, a longitudinal setting has allowed us to evaluate
the resilience of the rat microbiome after HST and to monitor the
disease severity index after withdrawal of DSS treatment.
Our study not only confirmed previous studies regarding the
increase in DAI and histological scores and the decrease in colon
length upon DSS treatment but also revealed a lower microbial di-
versity in stools, as well as in colonic tissues. These characteristics
are also observed in both UC and CD patients [6,39] and are more
marked in the latter [7]. Many studies have shown that rat models
of DSS-induced colitis share more features with UC than CD pa-
tients [19,40], from a structural, clinical and ultrastructural point
of view. Our comparison at microbiome level also confirmed that
the rat model of DSS-induced colitis was relatively closer to UC
than to CD patients.
In an attempt to understand the mechanism underlying a fae-
cal microbiota transplantation as a potential treatment for IBD, we
transferred a single stool collected from a healthy human donor to
a humanised DSS-induced colitis rat model. Our findings revealed
an improvement in several clinical and microbial variables. The rel-
ative recovery of colon length in response to HST confirmed an ef-
fect (direct or indirect) of an unaltered stool microbiota on modi-
fying the structure of the colon. This effect overpowered the action
of DSS, as its treatment in group E-HST2 was maintained until the
end of the study. However, a complete restoration of colon length
was not seen even after withdrawal of DSS treatment 40 days be-
fore the end of the study. This result is not consistent with the
finding of a previous study by Bento et al. using a mouse model
of DSS-induced colitis [34]. Those authors demonstrated completeestoration of colon length after withdrawal of DSS treatment. The
iscrepancy between studies could be attributable to the dose of
SS used (administration of 5% DSS for 5 days before a treatment
f 2% for 17 days) in our work. Instead, in Bento et al., DSS was
sed at only 2% for 20 days. Furthermore, the transfer of a healthy
uman stool allowed the amelioration of clinical manifestations,
eading to a significant decrease in the DAI scores, which were
orrelated with the relative abundance of several microbial gen-
ra in colonic samples. Interestingly, an unknown Christensenel-
aceae genus presented one of the highest negative correlations
ith DAI scores, and thus with disease severity. This genus was
reviously detected in a higher relative abundance in healthy indi-
iduals compared to IBD patients [7] and in normal weight individ-
als compared to overweight subjects [41], thereby validating its
ole in maintaining a healthy status. The S24-7 family, another re-
arkable group of bacteria, was depleted upon DSS treatment but
ncreased after DSS withdrawal. Moreover, it was found to be pos-
tively correlated with colon length. This result is consistent with
previous study showing that S24-7 was depleted in a model of
ype 1 diabetes [42], thereby suggesting that this bacterial group
ay be a good candidate for maintaining homeostasis.
Moreover, HST led to a significant restoration of microbiome
lpha-diversity in stool samples but not in colonic tissues unless
SS treatment was withdrawn. This observation indicates that HST
lone was not sufficient to correct dysbiosis in mucosal tissues
hen inflammation was maintained. To the best of our knowledge,
here are currently only four randomised published clinical trials
n FMT in patients with UC [10,43–45]. All of them showed low ef-
cacy of the treatment (between 20 and 30% of success rate), with-
ut a clear understanding of the clinical events because of the ob-
ious limitations of working with patients. Our study has pointed
ut possible reasons why FMT alone was not sufficient to treat
BD and recommends evaluation of the effect of anti-inflammatory
rugs on FMT treatment efficacy. Moreover, pre-clinical models,
uch as the present one, allow the analysis of a wide range of clin-
cal features, including intestinal length, and also mucosal tissue
arvesting and a long-term follow-up, which would not be easily
erformed with patients.
Our study shows for the first time that a conventional rat
odel, more reflective of human microbiota, is a potential alter-
ative to a mouse model to study microbe-host relationships in
uman disease. We demonstrate that a healthy stool transfer com-
ensates faecal dysbiosis, with a restoration of alpha-diversity and
n increase in the relative abundance of health-related genera. In
ddition, we show that a single faecal transplantation also cor-
ects, to some extent, colonic tissue alterations, leading to a rela-
ive restoration of colon length, and a decrease in epithelium dam-
ge and disease severity. Finally, our data suggest that new strate-
ies based on the combination of anti-inflammatory drugs with
MT may allow a better clinical outcome in IBD patients.
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